GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients

BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial

BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma’s TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

Outlines the Clinical Power of Immune Engagement with IL-15 Containing TriKEs BEVERLY…

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

Up to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient’s Endogenous…

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

BEVERLY HILLS, Calif., March 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry

Personalized Medicine Should Be At The Top Of Your List In 2021 & Here’s Why

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors

BEVERLY HILLS, CA / ACCESSWIRE / November 19, 2020 / GT Biopharma,…

GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

BEVERLY HILLS, CA / ACCESSWIRE / November 18, 2020 / GT Biopharma,…

GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors

BEVERLY HILLS, CA / ACCESSWIRE / November 17, 2020 / PGT Biopharma,…